Farallon Capital Management has established a new, significant stake in Tyra Biosciences (TYRA), a clinical-stage biotechnology company. According to its quarterly disclosure, the investment firm acquired 3.58 million shares, valued at approximately $137.15 million as of the report's date.
This investment information was made public in a 13F filing on August 14, 2026, but reflects the firm's holdings as of March 31, 2026. Tyra Biosciences is focused on developing precision medicines for cancer. During the first quarter of 2026, the company reported progress in its clinical trials for dabogratinib, an oral therapy aimed at FGFR3-driven cancers, and ended the quarter with $383.5 million in cash and marketable securities.